Block 3 material simplified (GIT meds) Flashcards

1
Q

H2 Blockers

MOA:

Clinical uses:

Adverse effects:

A

Cimetidine, Famotidine, & Nizatidine

MOA:
Inhibit H2 receptors to reduce H+ secretion from gastric parietal cells

Clinical uses:
Peptic ulcers
Gastritis
Mild esophageal reflux

Adverse effects: mostly Cimetidine
1) Inhibits CYP450 (drug interactions)

2) Antiandrogenic
(prolactin release, gynecomastia, impotence, low libido)

3) Cross BBB & placenta
(confusion, headaches, & dizziness)

4) Elevated CK (reduced renal clearance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Cimetidine, Famotidine, & Nizatidine

MOA:
Inhibit H2 receptors to reduce H+ secretion from gastric parietal cells

Clinical uses:
Peptic ulcers
Gastritis
Mild esophageal reflux

Adverse effects: mostly Cimetidine
1) Inhibits CYP450 (drug interactions)

2) Antiandrogenic
(prolactin release, gynecomastia, impotence, low libido)

3) Cross BBB & placenta
(confusion, headaches, & dizziness)

4) Elevated CK (reduced renal clearance)

A

H2 Blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Proton Pump Inhibitors

MOA:

Clinical uses:

Adverse effects:

A

Omeprazole, Lansoprazole, Esomeprazole, Pantoprazole, & Dexlansoprazole

MOA:
Irreversibly inhibits H+/K+ ATPase in gastric parietal cells
(needs acidic pH take before food)

Clinical uses:
Peptic ulcers
Gastritis
GERD
Zollinger Ellison syndrome
H. pylori
Prophylaxis for stress-induced ulcers

Adverse effects:
1) High risk of C.diff infection
2) Pneumonia
3) Acute interstitial nephritis
4) Vit B12, Mg2+, & Ca2+ malabsorption (higher fracture risk in elderly)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Omeprazole, Lansoprazole, Esomeprazole, Pantoprazole, & Dexlansoprazole

MOA:
Irreversibly inhibits H+/K+ ATPase in gastric parietal cells
(needs acidic pH take before food)

Clinical uses:
Peptic ulcers
Gastritis
GERD
Zollinger Ellison syndrome
H. pylori
Prophylaxis for stress-induced ulcers

Adverse effects:
1) High risk of C.diff infection
2) Pneumonia
3) Acute interstitial nephritis
4) Vit B12, Mg2+, & Ca2+ malabsorption (higher fracture risk in elderly)

A

Proton Pump Inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the effects of overuse of Aluminum hydroxide (antacid)?

A

Constipation
Hypophosphatemia/Hypokalemia
Osteodystrophy
Proximal muscle weakness
Seizures

“CHOPS”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Constipation
Hypophosphatemia/Hypokalemia
Osteodystrophy
Proximal muscle weakness
Seizures

“CHOPS”

Are overuse of which antacid?

A

Aluminum hydroxide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the effects of overuse of Calcium carbonate (antacid)?

A

Hypercalcemia (milk-alkali syndrome)
Hypokalemia
Rebound acid increase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Hypercalcemia (milk-alkali syndrome)
Hypokalemia
Rebound acid increase

Are overuse of which antacid?

A

Calcium carbonate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the effects of overuse of Magnesium hydroxide (antacid)?

A

Diarrhea
Hyporeflexia
Hypokalemia
Hypotension
Cardiac arrest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Diarrhea
Hyporeflexia
Hypokalemia
Hypotension
Cardiac arrest

Are overuse of which antacid?

A

Magnesium hydroxide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bismuth & Sucralfate

MOA:

Clinical uses:

A

MOA:
They bind to the ulcers base to protect it from further damage & they allow HC0-3 secretion to reestablish the pH gradient in the mucous layer

Note:
Sucralfate needs acidic pH (give before meals) & AVOID PPI’S & H2 inhibitors

Clinical uses:
1) Improve ulcer healing
2) Travelers diarrhea (Bismuth)
3) H.pylori-induced gastritis (Bismuth)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MOA:
They bind to the ulcers base to protect it from further damage & they allow HC0-3 secretion to reestablish the pH gradient in the mucous layer

Note:
_______ needs acidic pH (give before meals) & AVOID PPI’S & H2 inhibitors

Clinical uses:
1) Improve ulcer healing
2) Travelers diarrhea (_______)
3) H.pylori-induced gastritis (________)

A

Bismuth & Sucralfate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Misoprostol

MOA:

Clinical uses:

Adverse effects:

A

MOA:
PGE1 analog that increases the production/secretion of bicarbonate from the gastric mucosa & reduces the secretion of acid to protect the lining

Clinical uses:
1) Prevent NSAID-induced peptic ulcers
2) Off label labor inducer (ripens the cervix)

Adverse effects:
Diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MOA:
PGE1 analog that increases the production/secretion of bicarbonate from the gastric mucosa & reduces the secretion of acid to protect the lining

Clinical uses:
1) Prevent NSAID-induced peptic ulcers
2) Off label labor inducer (ripens the cervix)

Adverse effects:
Diarrhea

A

Misoprostol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Octreotide

MOA:

Clinical uses:

Adverse effects:

A

MOA:
Long-acting somatostatin analog that inhibits the release of various splanchnic vasodilatory hormones

Clinical uses:
1) Acute varicocele bleeds
2) Acromegaly
3) VIPoma
4) Carcinoid tumor

Adverse effects:
1) Nausea/Cramps
2) Steatorrhea
3) Higher risk of cholelithiasis (due to CCK inhibition)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MOA:
Long-acting somatostatin analog that inhibits the release of various splanchnic vasodilatory hormones

Clinical uses:
1) Acute varicocele bleeds
2) Acromegaly
3) VIPoma
4) Carcinoid tumor

Adverse effects:
1) Nausea/Cramps
2) Steatorrhea
3) Higher risk of cholelithiasis (due to CCK inhibition)

A

Octreotide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Sulfasalazine

MOA:

Clinical uses:

Adverse effects:

A

MOA:
A combination of sulfapyridine (antibacterial) & 5-aminosalicylic acid (anti-inflammatory) that is activated by colonic bacteria

Clinical uses:
Ulcerative colitis
The ulcerative component of Chron’s

Adverse effects:
1) Malaise/Nausea
2) Sulfonamides toxicity
3) Reversible oligospermia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

MOA:
A combination of sulfapyridine (antibacterial) & 5-aminosalicylic acid (anti-inflammatory) that is activated by colonic bacteria

Clinical uses:
Ulcerative colitis
The ulcerative component of Chron’s

Adverse effects:
1) Malaise/Nausea
2) Sulfonamides toxicity
3) Reversible oligospermia

A

Sulfasalazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Loperamide

MOA:

Clinical uses:

Adverse effects:

A

MOA:
An agonist at μ-opioid receptors in the myenteric plexus to slow gut motility & increase electrolyte resorption (hardens poop & reduces frequency)

Clinical uses:
Diarrhea

Adverse effects:
Constipation
Nausea/Cramping

20
Q

MOA:
An agonist at μ-opioid receptors in the myenteric plexus to slow gut motility & increase electrolyte resorption (hardens poop & reduces frequency)

Clinical uses:
Diarrhea

Adverse effects:
Constipation
Nausea

A

Loperamide

21
Q

Ondansetron & Granisetron

MOA:

Clinical uses:

Adverse effects:

A

MOA:
5-HT3 antagonist that acts peripherally to reduce vagal stimulation & centrally as an antiemetic

Clinical uses:
Control post-op vomiting in chemo patients

Adverse effects:
1) Headache
2) Constipation
3) QT prolongation
4) Serotonin syndrome

22
Q

MOA:
5-HT3 antagonist that acts peripherally to reduce vagal stimulation & centrally as an antiemetic

Clinical uses:
Control post-op vomiting in chemo patients

Adverse effects:
1) Headache
2) Constipation
3) QT prolongation
4) Serotonin syndrome

A

Ondansetron & Granisetron

23
Q

Aprepitant

MOA:

Clinical uses:

Adverse effects:

A

MOA:
Substance P antagonists that blocks NK1 (neurokinin-1) brain receptors

Clinical uses:
Antiemetic to reduce nausea/vomiting in chemo patients

24
Q

MOA:
Substance P antagonists that blocks NK1 (neurokinin-1) brain receptors

Clinical uses:
Antiemetic to reduce nausea/vomiting in chemo patients

A

Aprepitant

25
Prochlorperazine & Metoclopramide MOA: Clinical uses: Adverse effects:
MOA: D2 receptor antagonist that increase acetylcholine's response in the upper Gi tract to promote gastric emptying (prokinetic effect) and reducing nausea and vomiting (antiemetic effect). AVOID in patients with a small bowel obstruction Clinical uses: Diabetic & post op gastroparesis Antiemetic Adverse effects: 1) Extrapyramidal symptoms (tardive dyskinesia & lower seizure threshold) 2) Drowsiness/Fatigue 3) Depression 4) Diarrhea 5) Drug interactions with digoxin & diabetic drugs
26
MOA: D2 receptor antagonist that increase acetylcholine's response in the upper Gi tract to promote gastric emptying (prokinetic effect) and reducing nausea and vomiting (antiemetic effect). AVOID in patients with a small bowel obstruction Clinical uses: Diabetic & post op gastroparesis Antiemetic Adverse effects: 1) Extrapyramidal symptoms (tardive dyskinesia & lower seizure threshold) 2) Drowsiness/Fatigue 3) Depression 4) Diarrhea 5) Drug interactions with digoxin & diabetic drugs
Prochlorperazine & Metoclopramide
27
Orlistat MOA: Clinical uses: Adverse effects:
Lipid lowering agent MOA: Inhibits gastric & pancreatic lipase to reduce breakdown & absorption of dietary fats (take with a fatty meal) Clinical use: Weight loss Adverse effects: 1) Abdominal pain 2) Flatulence 3) Bowel urgency/frequency 4) Steatorrhea (fat-soluble vitamin def)
28
MOA: Inhibits gastric & pancreatic lipase to reduce breakdown & absorption of dietary fats (take with a fatty meal) Clinical use: Weight loss Adverse effects: 1) Abdominal pain 2) Flatulence 3) Bowel urgency/frequency 4) Steatorrhea (fat-soluble vitamin def)
Orlistat
29
Bulk-forming laxatives MOA: Clinical uses: Adverse effects:
Psyllium & Methylcellulose MOA: Soluble fibers draw water into the gut's lumen to form a viscous liquid to trigger peristalsis Adverse effects: Bloating
30
Psyllium & Methylcellulose MOA: Soluble fibers draw water into the gut's lumen to form a viscous liquid to trigger peristalsis Adverse effects: Bloating
Bulk-forming laxatives
31
Osmotic laxatives MOA: Clinical uses: Adverse effects:
Magnesium hydroxide, Magnesium citrate, Polyethylene glycol, & Lactulose MOA: They are osmotic loads that draw water into the Gi lumen to trigger peristalsis Clinical uses: Constipation (all) Hepatic encephalopathy (Lactulose) Adverse effects: 1) Diarrhea 2) Dehydration 3) Metabolic alkalosis (overuse)
32
Magnesium hydroxide, Magnesium citrate, Polyethylene glycol, & Lactulose MOA: They are osmotic loads that draw water into the Gi lumen to trigger peristalsis Clinical uses: Constipation (all) Hepatic encephalopathy (Lactulose) Adverse effects: 1) Diarrhea 2) Dehydration 3) Metabolic alkalosis (overuse)
Osmotic laxatives
33
Lactulose MOA: Clinical uses:
MOA: A synthetic disaccharide that's not absorbed in the gut that is metabolized by gut flora to activate an osmotic effect to soften stool and promote bowel movements Clinical uses: 1) Constipation 2) Hepatic encephalopathy (It reduces ammonia absorption)
34
MOA: A synthetic disaccharide that's not absorbed in the gut that is metabolized by gut flora to activate an osmotic effect to soften stool and promote bowel movements Clinical uses: 1) Constipation 2) Hepatic encephalopathy (It reduces ammonia absorption)
Lactulose
35
Stimulants (laxatives) MOA: Clinical uses: Adverse effects:
Senna & Bisacodyl MOA: Stimulate the enteric nerves to contract the colon (induce pooping) Clinical uses: Constipation Adverse effects: 1) Diarrhea 2) Melanosis coli 3) Metabolic alkalosis (overuse)
36
Senna & Bisacodyl MOA: Stimulate the enteric nerves to contract the colon (induce pooping) Clinical uses: Constipation Adverse effects: 1) Diarrhea 2) Melanosis coli 3) Metabolic alkalosis (overuse)
Stimulants (laxatives)
37
Emollients (laxative) MOA: Clinical uses: Adverse effects:
Docusate MOA: Promotes the incorporation of water & fat into poop (more pooping) Clinical uses: Constipation Adverse effects: 1) Diarrhea 2) Metabolic alkalosis (overuse)
38
Docusate MOA: Promotes the incorporation of water & fat into poop (more pooping) Clinical uses: Constipation Adverse effects: 1) Diarrhea 2) Metabolic alkalosis (overuse)
Emollients (laxative)
39
Lubiprostone MOA: Clinical uses: Adverse effects:
Cl- channel activator MOA: It activates the type 2 Cl- channels in the small intestine to increase the amount of Cl- rich fluid into the intestine to stimulate intestinal motility and shortens intestinal transit time Clinical uses: women with IBS (predominantly constipation) Adverse effects: Category C (pregnancy)
40
Cl- channel activator MOA: It activates the type 2 Cl- channels in the small intestine to increase the amount of Cl- rich fluid into the intestine to stimulate intestinal motility and shortens intestinal transit time Clinical uses: women with IBS (predominantly constipation) Adverse effects: Category C (pregnancy)
Lubiprostone
41
infliximab, adalimumab, and certolizumab MOA: Clinical uses: Adverse effects:
MOA: anti-TNF monoclonal antibody Clinical uses: 1) IBD 2) Rheumatoid arthritis 3) Ankylosing spondylitis 4) Psoriasis Adverse effects: 1) predisposing to infection (reactivation of latent TB) 2) drug-induced lupus
42
MOA: anti-TNF monoclonal antibody Clinical uses: 1) IBD 2) Rheumatoid arthritis 3) Ankylosing spondylitis 4) Psoriasis Adverse effects: 1) predisposing to infection (reactivation of latent TB) 2) drug-induced lupus
infliximab, adalimumab, and certolizumab
43
_______ IDB treatment options includes: 1) Anti-TNF antibodies like infliximab, adalimumab, and certolizumab 2) Natalizumab 3) Cyclosporine 4) IV corticosteroids 5) Surgery
Severe
44
______IDB treatment options includes: 1) Anti-TNF antibodies like infliximab, adalimumab, and certolizumab 2) Oral corticosteroids 3) Methotrexate 4) Azathioprine/6 Mercaptopurine
Moderate
45
_______IBD treatment options includes: Budesonide (ileitis) Topical corticosteroids Antibiotics 5-Aminosalicylate
Mild
46
Liraglutide MOA: Clinical uses: Adverse effects:
GLP-1 agonist MOA: decrease glucagon release, decrease gastric emptying, increase glucose-dependent insulin release Clinical uses: Weight loss Adverse effects: 1) N/V 2) headache 3) nasopharyngitis 4) increase satiety
47
GLP-1 agonist MOA: decrease glucagon release, decrease gastric emptying, increase glucose-dependent insulin release Clinical uses: Weight loss Adverse effects: 1) N/V 2) headache 3) nasopharyngitis 4) increase satiety
Liraglutide